OraSure Technologies (NASDAQ:OSUR) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS

OraSure Technologies (NASDAQ:OSUR) issued its earnings results on Wednesday. The medical instruments supplier reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.07, FiscalAI reports. OraSure Technologies had a negative net margin of 66.42% and a negative return on equity of 18.57%. The business had revenue of $30.64 million for the quarter, compared to the consensus estimate of $29.10 million.

Here are the key takeaways from OraSure Technologies’ conference call:

• Q2 revenue exceeded guidance: Total revenue was $30.6 million, up 9.7% sequentially, led by stronger diagnostics demand and 9% sequential growth in Sample Management Solutions. GAAP gross margin improved 120 basis points sequentially to 43.5%.
• OraSure received FDA clearance for its Colli-Pee Dx urine collection kit for eight STI testing indications and FDA Emergency Use Authorization for its second-generation OraQuick Ebola rapid antigen test, creating potential launch-related growth opportunities.
• IntelliQuick CT/NG timing slipped: The company withdrew its FDA submission after agency discussions and no longer expects U.S. clearance or launch in 2026, although management plans to resubmit and maintained its 2026 growth outlook.
• International diagnostics initiatives are expanding, including localized HIV self-test supply programs and Sickle SCAN, whose 2026 revenue is growing twice as fast as in 2025. Sample Management Solutions is also seeing recovery across advanced genetic testing laboratories, microbiome collection, and research channels.
• The company ended the quarter with $161 million in cash and no debt, while operating cash flow was negative $9.9 million; management expects operating cash flow to reach break-even as it enters 2027. Q3 revenue guidance is $29.5 million to $32.5 million, with gross margin expected to remain near Q2 levels.

OraSure Technologies Stock Performance

NASDAQ:OSUR traded down $0.02 during trading hours on Wednesday, hitting $4.15. The company’s stock had a trading volume of 239,307 shares, compared to its average volume of 346,892. OraSure Technologies has a 52-week low of $2.08 and a 52-week high of $4.58. The business’s 50-day moving average is $4.17 and its two-hundred day moving average is $3.41. The company has a market capitalization of $285.73 million, a PE ratio of -3.99 and a beta of 1.00.

Insider Activity at OraSure Technologies

In related news, Director Steven Kyle Boyd bought 25,000 shares of the firm’s stock in a transaction on Thursday, May 14th. The shares were bought at an average cost of $2.99 per share, for a total transaction of $74,750.00. Following the transaction, the director owned 113,462 shares of the company’s stock, valued at approximately $339,251.38. This trade represents a 28.26% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 4.70% of the company’s stock.

Hedge Funds Weigh In On OraSure Technologies

Large investors have recently made changes to their positions in the stock. Odyssean LLC acquired a new stake in shares of OraSure Technologies in the fourth quarter valued at about $162,000. NewEdge Advisors LLC grew its position in OraSure Technologies by 32,595.9% during the first quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier’s stock worth $161,000 after buying an additional 47,590 shares during the period. Jump Financial LLC acquired a new position in OraSure Technologies during the fourth quarter worth about $131,000. Russell Investments Group Ltd. increased its holdings in OraSure Technologies by 30.6% in the third quarter. Russell Investments Group Ltd. now owns 38,498 shares of the medical instruments supplier’s stock valued at $124,000 after buying an additional 9,012 shares in the last quarter. Finally, Sei Investments Co. increased its holdings in OraSure Technologies by 16.4% in the third quarter. Sei Investments Co. now owns 32,244 shares of the medical instruments supplier’s stock valued at $103,000 after buying an additional 4,536 shares in the last quarter. Hedge funds and other institutional investors own 93.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on OSUR. Weiss Ratings raised shares of OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Wall Street Zen lowered OraSure Technologies from a “hold” rating to a “sell” rating in a report on Sunday. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $3.00.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.